ebook img

Seminars in Respiratory Medicine 2003: Vol 24 Index PDF

15 Pages·2003·3.6 MB·English
by  
Save to my drive
Quick download
Download
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview Seminars in Respiratory Medicine 2003: Vol 24 Index

Author index 24, 2003 Anaiss Hansell, David M., 377, 585 Pavlovic, Jelena, 161 Anderson, Paula, Hartman, Thomas E., 419 Pignatti, Pier Franco, 179 Angtuaco, Sylvia S. O., 307 I laiby, Niels, 703 Pilewski, Joseph M., 749 \ rroliga, Alehandro C., 233 Pe letti, Vener ino, 455, 457 \ er, William R., 273 lannuzzi, Michael C., 135, 223 Quinn, John P.,61 3araldo, Simonetta, 465 Jackson, Kara, 663 Belperio, John A., 499 Jarjour, Nizar J., 229 Ravenel, James G., 427 Budey, Marie M., 233 Jones, Ronald N., 121 Remy, } ucques, 333 B lising 3 Judd, Brooke G., 315 Remy-Jardin, Martine, 333 Bush, Andre Richards, Michael, 3 Kangesan, I., 205 Rubin, Bruce K., 619, 737 Keane, Michael P., 499 Rybicki, Benjamin A., 137 Keicho, Naoto, 607 Kerr, Kim M., 273 Saetta, Marina, 465 Keyser, Rebecca, 663 Sateia, Michael J., 315 Kim, Nick H., 273 Schechter, Michael S., 639 King, Talmadge E., 567 Schiirmann, Manfred2,1 3 Koch, Christian, 703 Schwartz, David A., 185 Kosiborod, Mikhail, 245 Sexauer, William P., 717 Krachman, Samuel L., 297 Silverman, Edwin K., 151 Krawiec, Marzena E., 22° ) Sobel, J. D.,99 Kudoh, Shoji, 607 Speert, David P., 671 Strieter, Robert, 499 Lake, Kathleen, 499 Swensen Stephen J , 445 Lee-( hiong, Teofilo I , 231, 263 Leigh, Margaret6,5 3 Tanoue, LynnT ., 287 Limper, Andrew H., 445 Tazelaar, Henry D., 499, 543 LiPuma, John J., 681 Chursky, Karin, 3 Liu, Stephen, 315 linkle, Sally S., 169 Luisetti, Maurizio, 179 Lynch, David A., 365 \ IZquez, }., 99 Lynch, Joseph P., 1, 393, 499, S Veeraraghavan, S., 205 Verschakele n, Johny ” 47 >) MacDonald, Sharyn, 357 Maki, Dennis G., 23 Wackers, Frans J. Th., 245 M iliarik, Mary J ; 223 Weber, Ste phen G., 49 Marras, Theodore K., 531 Weinstein, Robert A., 113 Matthay, Richard A., 231 59+93 Weiss, Daniel J., 749 McAdams, H. Page, 427 Wells, Athol U., 331, 346, Miller, York E., 197 585 Miiller, Nestor L. Weston, Ainsley, 169 Myers, Jeffrey | White, Eric S., 543 Wiedemann, Herbert P., 23P3e) Nicholson, Andrew G., 3 Wozniak, DanielJ ., 663 rallati, Sa ina, Nick, Jerry A., 693 Wright, Joanne L., 577 Gold, Howard S., 49 Grazziutti, Monica, 89 Patterson, Jane E., 7 , New York, NY Subject Index © VOLUME 24, 2003 Ichrobacter (alcaligenes) xylosoxidan Anomalous pulmonary venous return, right ventriclular cystic fibrosis pathogen emergence and, 681-688 dysfunction and, 309-313 infection control with cystic fibrosis, 703-712 Antibiotic aerosolization, cystic fibrosis patients, 717-725 Active cycle of breathing technique (ACBT), airway Antibiotic/antimicrobial resistance clearance in cystic fibrosis, 729-733 Acinetobacter Baumannit infection in ICU and, 69-75 Acute respiratory distress syndrome (ARDS), genetics biofilm formation and, 663-669 studies, 161-166 community-acquired and nosocomial pathogens, 121-130 \deno-associated virus, cystic fibrosis, gene therapy cystic fibrosis, aerosolized antibiotic therapy, 722-725 assessment, 749-763 epidemiology and intervention, 113-118 \denovirus, cystic fibrosis, gene therapy assessment, 7 extended-spec trum beta-lactamases and, 79-85 Adhesion molecules, macrolide biological response intensive care unit infections, epidemiology and prevelance, modification, cystic fibrosis/bronchiectasis, 737 3 16 Airflow obstruction methicillin-resistant infection and treatment, 37-44 bronchiolar disorders, classification and diagnosis, Pseudomonas aeruginosa, \CU infections, 61-67 connective tissue ¢ liseases and bronchiolar disorders, vancomycin-resistant enterococcus (VRE), 49-56 Aur pollution Antibiotic lock solutions, line sepsis in ICU, prevention, bronchiolitis etiology and, 577-582 diagnosis, and management, 30-33 outcomes in cystic fibrosis patients and, 639-648 Antifungal agents, Candida spp su sceptibility, 101-108 \ir trapping Anti-infective catheter surfaces, line sepsis in ICU, extrinsic allergic alveolitis, 419-424 prevention, diagnosis, and management, 28-33 small airway imaging, 478-483 Anti-infective therapy, line sepsis in ICU, prevention, irway disease diagnosis, and management, 30-33 biofilms and, 663-669 \ntimycobacterials, nontuberculous mycobacteria and cystic bronchiolitis obliterans syndrome, in transplant patients, fibrosis, 697-700 508-519 Anti-neutrophil cytoplasm autoantibody positive vasculitis clearance techniques, 727-733 (ANCA) macrolide biological response modification, cystic bronchiolar disorders diagnosis, 461-462 fibrosis/bronchiectasis, 740-744 computed tomography, 429-433 Airway gene delivery, cystic fibrosis, gene therapy assessment, Asbestos exposure, occupational-induced bronchiolitis, 755-763 577-582 Alemtuzumab Campath 1H), bronchiolitis obliterans \spergillomas, sarcoidosis, compute d tomographic imaging, 397-415 syndrome, in transplant patients, 519 Allergens, environmental asthma, 185-192 Association studies Allergic bronchopulmonary aspergillosis (ABPA), 621-627 chronic obstructive pulmonary disease (COPD) genetics, Allograft rejection, bronchiolitis obliterans syndrome and, 151-157 499-519 lung cancer susceptibility and, 199-202 Allorecognition, bronchiolitis obliterans syndrome and, sarcoidosis genetics, 213-218 499-519 tuberculosis resistance and susceptibility, genetic factors, Alpha 1-antitrypsin (AAT) deficiency 223>3 -- 227 bronchiectasis and, 622-627 Asthma chronic obstructive pulmonary disease (COPD), 151-157 bronchiolar histopathology and, 491-497 Alveolar hypoventilation disorders, cor pulmonale, genetics and evnrionment and, 185-192 epidemiology and pathogenesis, 233-242 small airway imaging, 483 Aminoglycosides Atrial septal defects, right ventriclular dysfunction and, aerosolized antibiotics for cystic fibrosis, 717-725 308-313 resistance, extended-spectrum beta-lactamases, 83-85 Autogenic drainage, airway clearance in cystic fibrosis, Amphotericin B, candidiasis therapy with, 99-108 729-733 \ngiocardiography, right ventricular morphology and Azithromycin, bronchiolitis obliterans syndrome, in function, 253-260 transplant patients, 518-519 Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE/VOLUME 24, NUMBER6 2003 QDDb Bronchoalveolar lavage (BAI cute respiratory distress syndrome (ARDS) genetics, 164-166 bronchiolar disorders connective tissue disease, 545-560 differential diagnosis, 460—462 bronchiolitis obliterans diagnosis bone marrow transplant patients, 536-539 heart-lung/lung transplant patients, 505-519 respiratory }b ronchiolit] is-interst- itial 1] lung d|i sease, Bronchodilators, airway clearance in cystic fibrosis, Bronchostenosis, sarcoid losis, compute 1 tomograp!| 397-415 imaging, Burkholderia cepacia compl cystic fibrosis pathoge n emergenc¢ i, 681-688 infection control with cystic fibrosi 2 non-genetic factors n cysti« t;} Dro 639-648 i nervous systen tomographic in Central venous « atheters, diagnosis, and manage SUBJECT INDEX 1-5 Centrilobular nodules chronic obstructive pulmonary disease, pulmonary bronchiolar disorders diagnosis, 460—462 hypertension and, 263-270 extrinsic allergic alveolitis, 419-424 cystic fibrosis and, 323-328 Cephalosporins, extended-spectrum beta-lactamases, 81-82 epidemiology and pathogenesis, 233-242 Cephamycin resistance, extended spectrum beta-lactamases, sleep apnea in restrictive lung disease and neuromuscular 82 QS disease patients, 297-303 Chemokines Corticosteroids, bronchiolitis obliterans syndrome, in bronchiolitis obliterans syndrome and, 499-519 transplant patients, 518-519 macrolide biological response modification, cystic Cost analysis, intensive care unit infections, epidemiology fibrosis/bronchiectasis, 739-744 and prevelance, 3-16 Chest X-ray, right ventricular morphology and function, Coughing, airway clearance in cystic fibrosis, 729-733 248-260 Critical care, vancomycin-resistant enterococcus (VRE), 49-56 Chronic airway infection, diffuse panbronchiolitis diagnosis Cross-infection, with cystic fibrosis, patient cohorting and, and pathophysiology, 607-614 703-712 Chronic beryllium disease (CBD). See Beryllium disease Cryptogenic bronchiolitis, etiologsy and pathophysiology, Chronic obstructive pulmonary disease (COPD) 571-573 cor pulmonale Cryptogenic organizing pneumonia epidemiology and pathogenesis, 233-242 connective tissue diseases and, 543-560 pulmonary hypertension with, 263-270 diagnosis and pathophysiology, 595-603 genetics studies, 151-157 high-resolution computed tomography (HRCT), idiopathic disseminated bronchietasis genetics and, 179-183 small airway imaging, 481-483 lung cancer susceptibility and, 199-202 Cutaneous antisepsis, line sepsis in ICU, prevention, »ccupational-induced bronchiolitis, 577-582 diagnosis, and management, 28-33 small-airway pathophysiology, 465-471 Cyclophosphamide (CP), bronchiolitis obliterans syndrome, Chronic otitis, primary ciliary dyskinesia and, 657-659 in transplant patients, 518-519 Churg-Strauss syndrome (CSS), computed tomography Cyclosporin A, bronchiolitis obliterans syndrome, in transplant patients, 518-519 res, primary ciliary dyskinesia and, 653-659 CYP1A1 polymorphism, lung cancer susceptibility studies, negativest iphylococ ci, methicillin-resistant 197-202 infection and treatment, 37-44 Cystic fibrosis l"1i agen Vascula' r a}i sease verosolized antibiotic therapy, 717 pulmonary hypertension, 2287-29 3 uirway clearance techniques, 727 vasculitides, computed tomography, 433 Burkholderia and pathoge n emergence, 681-688 yMmunity-acquired infection, antibiotic/antimicrobial cor pulmonale and, 323-328 resistance, global epidemiology, 121 130 gene therapy assessment, 749-763 ymputed tomography. § alse High resolution computed genetics studies, 629-636 tomography HRCI idiopathic disseminated bronchietasis genetics and, } ronic thromboembolic1 pul1 monary lh ypertension, 179-183 infection control, patient cohorting and, 703-712 usculitis, 427-433 macrolide modifiers, 737-744 lar morphology and function,2 5 non-genetic influenocn,e s 639-648 diagnosis ind manage nontuberculous mycobacteria in, 693-700 primary ciliary dyskinesia comparisons with, 653-659 4 bronchiecta igi ht vs eC! icchi u lar dysfunction, research overview, 619-6 +~ i brosis transmembrane conductance regulator gene disease ir complications, 5 essment, 749-763 organizin 601-603 netic screening 11 ; ' , _ cicatritial Dro idiopathic disseminated bronchietasis genetics and, 179-183 macrolide biological response modification, 741-744 issue diseases ¢ nontuberculous mycobacteria and mutations of, 693-700 Dp ithology, 489 Ps) eudomonas aeruginos z and lesion pathogenesis, 671-6 small airway imagin 481 ystic lung disorders, sarcoidosis, Ccomy uted tomographi yntrast ventricul] ography imaging for differential diagnosis, 405-415 r pul, monale and | chronic ob|D struc .t ive pulmonary disease, ‘ytokines 266 270 bronchiolitis obliterans syndrome and, 499-519 right ventricular morphology ind function, 258-260 chronic obstructive pulmonary disease (COPD) genetics, OI pulmon ile 155-157 bronchiectasis and, 622-627y o macrolildied e Diolboiogliogciaca l responses e modifliifci ation, Cystic cardiovascular abnormalities, sleep-disordered breathin y fibrosis/bronchiectasis, 737-744 and, 315-320 pulmonary fibrosis genetics, 208-211 »bliterans syndrome, in Emphysema, bronchiolar histopathology and, 492-497 -m pirical I tthheer apy, anStiboio tic/ansttiimmiiccrroobhiiaall rrees istanc—e , syndrome, if community-acquired and nosocomial infection, 121-130 »nterobacteria, antibiotic/antimicrobial resistance, ind. 556-560 community-acquired ht and nosocomial infection, global epidemiology, 125-130 HRCT), 365-374, ~“nterococcus antibiotic/antimicrobial resistance, community-acquired and nosocomial infection, global epidemiology, 125-130 pathogenesis, 49-56 Environmental factors asthma genetics and, 185-192 bronchiolitis and occupational health and safety, 577 idiopathic disseminated bronchietasis genetics and,j 179-183 lung cancer susceptibility and, 199-202 , , , ; lung disease epidemiology, 13 Eosinophilic pneumonia, drug Epidemiologic studie el ae antiDd1otic/antimicroDial res ‘ lobal epidemiology, 121 LIU intensive care units (ICUs), 113 |h igh| -resolu1 tion computed tomograp nfections in intensive ung disease genetics, moki' ng-related int tuberculosis resistance factors, 223-22 I pigenetics, cystic fibros = Epithelia aye! cystic fibrosis, g Pseudomonas a pat }n ogenesis, 6 smmaallll -airway path| ophyReseit o Equilibrium radionuclide an morphology ind fu Erythromycin diffuse panbronchiolitis diagnosis and therapy, 61 -s ec ¢s , il macrolide Diological response modification, cyst fibrosis/bronchiectasis, 44 um Deta-lactamases ind, Exercise, airway clearance in cystic fibrosis and, 731-73 Exhaled nitrous oxide, bronchiolitis obliterans diagnosis and, 505-519 Expiratory computed tomography, small airway imaging, 478-483 Extended-spectrum beta-lactamases, epidemiology and pathogenesis, 79-85 Extracorporeal photochemotherapy (ECP), bronchiolitis obliterans syndrome, in transplant patients, 518-519 Echinocandin compounds, cz Extrinsic a lle rgic alveolitis, high-resolution computed Ex I On ardi grapny tomography (HRCT), 419-424 Familial aggregation, chronic obstructive pulmonary disease right ventricular morphology and f (COPD) genetics, 153-157 EGTA, cystic fibrosis, gene therapy assessment, 75 Familial studies, environmental asthma, 185-192 Eisenmenger syndrome, right ventriclular dysf Flock worker's lung, etiology and pathophysiology, 569-573 307-313 Fluconazole, candidiasis therapy with, 99-108 SUBJECT INDEX Fluoroquinolone resistance, extended-spectrum beta- Hemodynamics, right ventricular morphology and function, lactamases, 83-85 250-260 Focal solitary cryptogenic organizing pneumonia, differential Hepatic sarcoidosis, computed tomographic imaging of, 414-415 diagnosis, 598-603 Follicular bronchiolitis Heritability studies, lung cancer susceptibility and, 199-202 connective tissue disease and, 551-560 Hermansky-Pudlak syndrome, pulmonary fibrosis genetics, small airway imaging, 480-483 208-211 Forced exhalation, airway clearance in cystic fibrosis, 729-733 High-frequency chest-wall compression, airway clearance in cystic fibrosis, 730-733 Gastroesophageal reflux (GER), airway clearance in cystic High-resolution computed tomography (HRCT) fibrosis and, 731-733 bone marrow transplantation and bronchiolitis obliterans, Gastrointestinal gene expression, cystic fibrosis genetic screening, 635-636 bronchiolar disorders, classification and diagnosis, 457-462 Gatekeeper genes, lung cancer susceptibility and, 199-202 bronchiolitis obliterans diagnosis and, 505-519 Gene-environment interactions, asthma genetics, 185-192 diffuse infiltrative lung disease, 347-354 Gene therapy, cystic fibrosis, assessment of, 749-763 diffuse parenchymal lung disease management, 357-362 Genetics studies drug-induced lung disease, 445-452 acute respiratory distress syndrome (ARDS), 161-166 extrinsic allergic alveolitis, 419-424 beryllium disease risk, 169-175 fibrotic idiopathic interstitial pneumonia, 365-374 chronic obstructive pulmonary disease, 151-157 parenchymal lung disease, clinical applications, 333-344 cor pulmonale and cystic fibrosis, 324-328 cystic fibrosis patients, 629-636 sarcoidosis, 393-415 environmental asthma, 185-192 small airway disorders, 437-442 idiopathic disseminated bronchietasis, 179-183 imaging studies, 473-484 lung cancer susceptibility, 197-202 smoking-related parenchymal lung disease, 377-389 lung disease epidemiology, 137-146 Histopathology primary ciliary dyskinesia, 653-659 bronchiolar disorders pulmonary fibrosis, 205-211 connective tissue disease, 549-560 sarcoidosis, 213-218 high-resolution computed tomography (HRCT), tuberculosis resistance and susceptibility, 223-227 347-354 Genome sequencing, Pseudomonas aeruginosa, \CU infections, small-airw ay characteristics, 489-497 61-67 sarcoidosis, computed tomographic imaging and, Genomic instability, lung cancer susceptibility studies, 197-202 403-415 Genotype-phenotype correlation Hospital-related infections. See Nosocomial infection biofilm formation and, 668-669 Human Genome Project, lung disease epidemiology, 137-146 cystic fibrosis genetics, 629-636 Human leukocyte antigen (HLA) cystic fibrosis pathogen emergence and, 681-688 beryllium disease genetics, 169-175 lung disease epidemiology, 137-146 bronchiolitis obliterans syndrome and, 499-519 pulmonary fibrosis genetics, 205-211 Hydrocephalus, primary ciliary dyskinesia and, 658-659 Giant cell arteritis, computed tomography, 428-433 Hypercapnic challenge, cor pulmonale and sleep apnea in Graft versus host disease, bone marrow transplantation and restrictive lung disease and neuromuscular disease bronchiolitis obliterans, 531-539 patients, 299-303 Gram-negative resistance, extended-spectrum beta- Hypersecretion inhibition, diffuse panbronchiolitis diagnosis lactamases and, 79-85 and therapy, 612-614 Granulomatosis, pulmonary vasculitis, 427-43493 5 Hypersensitivity pneumonitis Granulomatous inflammation, sarcoidosis, 393-415 drug-induced lung disease, 450-452 Ground-glass attenuation, bronchiolar disorders diagnosis, high-resolution computed tomography (HRCT), 419-424 460-462 small airway imaging, 482-483 Growth factors, bronchiolitis obliterans syndrome, in Hypertonic saline, airway clearance in cystic fibrosis, transplant patients, 512-519 GSTM1 polymorphism, lung cancer susceptibility studies, Hypoxemia, cystic fibrosis and cor pulmonale, 323-328 197-202 Hypoxic challenge, cor pulmonale and sleep apnea in restrictive lung disease and neuromuscular disease Hand hygiene, antibiotic/antimicrobial resistance, intensive patients, 299-303 care units (ICUs), 113-118 Hypoxic vasconstriction, cor pulmonale, epidemiology and Haplotypes, lung disease epidemiology, 137-146 pathogenesis, 233-242 Heart disease cor pulmonale, epidemiology and pathogenesis, 233-242 Idiopathic bronchiolitis, etiology and pathophysiology, cystic fibrosis and cor pulmonale, 325-328 567-573 Heart-lung transplantation, bronchiolitis obliterans syndrome Idiopathic interstitial pneumonia, diagnosis and with, 499-519 pathophysiology, 595-603 1-8 SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE/VOLUME 24,NUMBER6 2003 ' , , , ; Interferon, nontuberculous mycoba 1 and cystic fibrosi 699-700 rleukin-2 receptor yndrome, rstitial| : : r pulmonale, ypt 595-603 rh-resolut . - King and,h HRCT ventricular th COPD cystic fibs Lower respiratory tract infection cor Lumen abnormalitie 470-471 Lung biopsy bronchiolar disorder connective tissue ¢ 11S€ 5. .F ) 560 histopathology, 49] ind prev lar ct n, bronchiolitis ob| liter in narrow transplant patient nd management, 2 3-33 536-539 ction and treatment Lung cancer venetic susceptibility studies, 1 small airway imaging, 476-48 SUBJECT INDEX 1-9 Mortality rates ’ aerosolized antibiotic therapy, 722 chronic thromboembolic pulmonary hypertension, biofilm formation and, 664-669 273-283 bone marrow transplantation and, 531-539 intensive care unit infections, epidemiology and prevelance, cor pulmonale, epidemiology and pathogenesis, 233 242 3-16 sat sin drug-induced disease, high-resolution computed Mosaic attenuation, small airway imaging, 477-483 > tomography (HRCT), 445-452 Mosaic perfusion renetics and epidemiology, 137-146 bronchiolar disorders diagnosis, 459-462 ; . ae ; ugh resolution computed tomography analysis, 333-344 mall airway imaging, 47 483 nontuberculous mycobacteria and, 695-700 Mouth occlusion pressure, cor pulmonale and sleep apnea in transplantation restrictive lung disease and neuromuscular diseas¢ obliterans syndrome with, 499-519 patients, 299-303 yus mycobacteria and cystic fibrosis, 699-700 Mucociliary clearance te accumulation, diffuse panbronchiolitis diagnos cystic fibrosis, techniques for, 7 | pathophysiology, 608-614 ene therapy for cystic fibrosis, 758-763 tic bronchitis/bronchiolitis, bronchiolitis obliteran macrolide biological response modification, cystic ndrome,i n tran it ients, 507-519 fibrosis/bronchiectasis, 740-744 primary ciliary dyskinesia and, 653-659 : . Mucolytics, airway clearance in cystic fibrosis, osis/bronchi is, biological response Multifactorial disorders, idiopathic dissemin; Y lit) ation, 737-744 bronchietasis genetics and, 179-183 HOULITIA panbronchi}o litis diagnosis and pathophysiology, Multigenic studies, acute respiratory distress syndrome 607-614 ARDS) genetics, 161-166 pic airways, all < maging, 476-483 Muscular dystrophy, cot pulmonale and sleep apnea in restrictive lung d}i sease and neuromuscular diseas« tive pulmonary disease, patients, 300-303 Mutation classification 250-260 cystic fibrosis genetics6,2 9 636 compatibility complex (MHC Pseudomonas aeruginosa and cystic fibrosis lesion s obliterans syndrome,i n transpIl ant patients, p| a s, 671-6 Myasthenia gravis, pulmonale] and s1l eep apnea in 5} m 1 , ' lary fibrosis genetics, z Z restrictive lung disease and neuromuscular disease ase ' til s genetics, 213-2 patients, 302-303 n guidelines Mycobacteria (nontuberculous), cystic fibrosis and, 693-700 Mycobact 1m aos s, cystic fibrosis and, 693-700 ive pulmonary disease, Vycobacterium at ymplex, ic fibrosis and, 693-700 Mycobacterium tub s, tuberculosis resistance and } 1 1 j 1 392.997 inheritance, tuberculosis resistance and susceptibility, genetic factors, 2297-22 eptibility, genetic fa , 223-227 Mycoph| enolate mofetil, bronchiolitis obliterans syndrome, n resistance, staphylococci infection and treatment transplant patients, 515-519 $4 Myotonic dystrophyc,o r pulmonale and sleep apnea in xate, bronchiolit1 is obLtl iterans rome, 1n restrictive lu }l i ind ] neuromuscular disease insplant patients, 51; patients, 300 stability, pult sarcoid ang s and granulomatosis, sarcoidosis vangiitis, cor l i tom raph 131-433 computed tomogt phi ging, 398-415 syndrome, 621-62 Neonatal intensive care t Us), infectionsi n issociated j airwa 1iSe< epidemiology " | 1 topathology ind, 7 Neuroendocrine cell hyperplasia, bronchiolar fibrosis, al-induced bronchiolitis, 577-5 459-462 Neutrophil accumulation lar disease and, 558 diffuse panbronchiolitis diagnosis and pathophysiology pulmonary hypertension and, 287-: 608-614 Modifier genes macrolide biological response modification, cystic ystic fibrosis genetics, 629-636 fibrosis/bronchiectasis, 737-744 Pseud nas aeruging osa and cystic fibrosis lesion primary ciliary dyskinesia and, 658-659 pathogenesis, 671-677 Nitric oxide, macrolide biological response modification, Molecular conjugates, cystic fibrosis, gene therapy cystic fibrosis/bronchiectasis, 739-744 assessment, 754-763 Nocturnal hypoventilation apnea, cot pulmonale in restrictive Molecular typing, Acinetobact zannii infection in ICI lung disease and neuromuscular disease patients and, and, 69-75 297-303 SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE/VOLUME 24,NUMBER6 2003 Ni tem (NANC), macrolide Pathogenesis infections in ICUs, epidemiology and prevelance, 3-16 line sepsis in ICU, prevention, diagnosis, and management, 23-33 nontuberculous mycobacteria, 694 700 Paattiiee nt con}o rting,g cystiticc ffiil brosis; , and ’ infe‘2 ction " conttrrooll, neuromuscul 1 § 703 Pediatric patients, pulmonary fibrosis genetics, 206-211 Percussion and p| ostural drainage (P&PD), airway clearance in cystic fibrosis, 729-733 Perfluorochemicals, gene therapy for cystic fibrosis, 759-763 Peribronchiolar fibrosis , bronchiolar histopathology and, 495-497 Phospholipids, macrolide biological resppoorn se modification, cystic fibrosis/bronchiectasis, 740-744 Pleural effusions, sarcoidosis, computed tomographic imaging, 396-415 Pneumoconiosis, extrinsic ullergic ilveolaintd,i s 419-424 Pneumonia. See a/so Ventilator ussisted pneumonia (VAP drug-induced lung disease, 445-452 fibrotic idiopathic interstitial pneumonia, high-resolution computed tom oT phy HRCI high-resolution computed tomography (HRCT diagnosis with, 347-354 managment and, 357-362 in intensive Care inits, epider uiology and prev: , ' , methicillin-resistant staphylococci nfection ind 1 treatment, Cy Poliomyelitis, restrictive lung dise a ase patie 301-303 Polyarteritis nodosa (PAN), puted tomography, 428-433 Polycations, cystic fibrosis rapy assessment, 758-763 Polymyositis, bronchiolar ind, 556-560 Positive expiratory pressure iv clearance fibrosis, 729-733 P>r eval]e nce studi|c intibiotic/antimicrobial , community-acquired ind nosocomial in 121-130 — , bronchiolitis oblite patients, 532 environmental is hn la, extended spectrum bet infections in intensive ca nontuberculous mycobacteria and cystic fibrosis, 696-700 — ws Primary ciliary dyskinesia, cystic fibrosis comparisons with, 3-659 P rognostic indijc atorros , nig } resolluitoti on ¢ ymnpmuutteedd tomography} HRCT), parenchymal lung disease, 35 7-362 2 Protease inhibitor (PI) Z, chronic obstructive pulmonary disease (COPD) genetics, 151-157 Protein synthesis, cystic fibrosis tr embrane regulator gene, 6 +9 636 aerosolized antibiotics for cystic fibrosis, 717-72 intibiotic/antimicrobial resistance, community acquired PSAD and nosocomial infection, global epidemiology, 4159-462 125-130 57 582 biofilm formation and, 663-669

See more

The list of books you might like

Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.